Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe.

IF 3.5 3区医学 Q1 DERMATOLOGY Dermatology and Therapy Pub Date : 2024-10-16 DOI:10.1007/s13555-024-01280-3

Peter Anderson, James Piercy, Jenny Austin, Simran Marwaha, Kent A Hanson, Ernest H Law, Gregor Schaefer, Samantha K Kurosky, Sergio Vañó-Galván

{"title":"Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe.","authors":"Peter Anderson, James Piercy, Jenny Austin, Simran Marwaha, Kent A Hanson, Ernest H Law, Gregor Schaefer, Samantha K Kurosky, Sergio Vañó-Galván","doi":"10.1007/s13555-024-01280-3","DOIUrl":null,"url":null,"abstract":"Introduction: Alopecia areata (AA) is an autoimmune disease that causes scalp, face, and/or body hair loss. Recently, oral treatments with kinases inhibition became the first approved therapies for severe AA. An understanding of the use and effectiveness of traditional therapies in real-world treatment settings is needed to guide integration of novel therapies into the treatment paradigm. This study aimed to describe traditional treatment patterns, dermatologists' reasons for therapy choice, and dermatologists' satisfaction with disease control among patients with AA.Methods: Data were drawn from the 2021-2022 Adelphi Real World AA Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with AA, conducted in France, Germany, Italy, Spain, and the UK. For each patient, using data from patient consultation and medical records, dermatologists reported % scalp hair loss (SHL), characteristics of current and prior AA therapies, and satisfaction with disease control.Results: Overall, 239 dermatologists provided data for 1720 patients with AA. Mean (SD) patient age was 35.8 (11.6) years, and 51% were male. Based on dermatologist perception, among patients with ≤ 10% SHL, 74% were experiencing mild AA, while ≥ 95% of patients with ≥ 50% SHL were experiencing severe/very severe AA. In patients with ≥ 50% SHL, the most common therapies received included systemic immunosuppressants (31%), topical corticosteroids (24%), and oral corticosteroids (24%). Among all patients who had switched therapies, 49%, 26%, and 24% switched because of worsening AA, lack of initial efficacy with prior treatment, and loss of response over time, respectively. Among those with SHL ≥ 50%, dermatologists reported satisfaction with current therapy in < 30% of patients.Conclusion: Dermatologists reported low satisfaction with traditional AA therapies used in patients with extensive SHL, with some patients discontinuing treatment because of worsening disease. This suggests more effective treatments are needed for patients with severe AA.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1007/s13555-024-01280-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Alopecia areata (AA) is an autoimmune disease that causes scalp, face, and/or body hair loss. Recently, oral treatments with kinases inhibition became the first approved therapies for severe AA. An understanding of the use and effectiveness of traditional therapies in real-world treatment settings is needed to guide integration of novel therapies into the treatment paradigm. This study aimed to describe traditional treatment patterns, dermatologists' reasons for therapy choice, and dermatologists' satisfaction with disease control among patients with AA.

Methods: Data were drawn from the 2021-2022 Adelphi Real World AA Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with AA, conducted in France, Germany, Italy, Spain, and the UK. For each patient, using data from patient consultation and medical records, dermatologists reported % scalp hair loss (SHL), characteristics of current and prior AA therapies, and satisfaction with disease control.

Results: Overall, 239 dermatologists provided data for 1720 patients with AA. Mean (SD) patient age was 35.8 (11.6) years, and 51% were male. Based on dermatologist perception, among patients with ≤ 10% SHL, 74% were experiencing mild AA, while ≥ 95% of patients with ≥ 50% SHL were experiencing severe/very severe AA. In patients with ≥ 50% SHL, the most common therapies received included systemic immunosuppressants (31%), topical corticosteroids (24%), and oral corticosteroids (24%). Among all patients who had switched therapies, 49%, 26%, and 24% switched because of worsening AA, lack of initial efficacy with prior treatment, and loss of response over time, respectively. Among those with SHL ≥ 50%, dermatologists reported satisfaction with current therapy in < 30% of patients.

Conclusion: Dermatologists reported low satisfaction with traditional AA therapies used in patients with extensive SHL, with some patients discontinuing treatment because of worsening disease. This suggests more effective treatments are needed for patients with severe AA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脱发治疗模式和满意度：欧洲真实世界跨部门调查的结果。

简介斑秃（AA）是一种导致头皮、面部和/或全身脱发的自身免疫性疾病。最近，口服激酶抑制剂成为首批获准治疗严重脱发症的疗法。我们需要了解传统疗法在实际治疗环境中的使用情况和效果，以指导将新型疗法纳入治疗范例。本研究旨在描述AA患者的传统治疗模式、皮肤科医生选择疗法的原因以及皮肤科医生对疾病控制的满意度：数据来自 2021-2022 年阿德尔菲真实世界 AA 疾病专项计划（Adelphi Real World AA Disease Specific Programme™），这是一项针对皮肤科医生和成年 AA 患者的横断面调查，在法国、德国、意大利、西班牙和英国进行。皮肤科医生利用患者咨询和医疗记录中的数据，报告了每位患者的头皮脱发（SHL）百分比、当前和之前 AA 治疗的特点以及对疾病控制的满意度：共有 239 名皮肤科医生为 1720 名 AA 患者提供了数据。患者的平均年龄为 35.8 (11.6)岁，51% 为男性。根据皮肤科医生的感知，在SHL≤10%的患者中，74%为轻度AA，而在SHL≥50%的患者中，≥95%为重度/极重度AA。在 SHL ≥ 50% 的患者中，最常接受的疗法包括全身性免疫抑制剂（31%）、局部皮质类固醇（24%）和口服皮质类固醇（24%）。在所有更换过疗法的患者中，49%、26% 和 24% 分别是因为 AA 恶化、之前的治疗缺乏初步疗效以及随着时间的推移失去反应而更换疗法。在SHL≥50%的患者中，皮肤科医生对当前疗法表示满意的患者不足30%：结论：皮肤科医生对用于大面积 SHL 患者的传统 AA 疗法的满意度较低，一些患者因病情恶化而中断治疗。这表明重度 AA 患者需要更有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.